Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.50 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104432 | 0.88 | POLB (0.53) | LTA4HKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL30063493 | 0.83 | LTA4H (0.58) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL545871 | 0.83 | LTA4H (0.58) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL17571469 | 0.81 | KDM4E (0.56) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL12130330 | 0.80 | LTA4H (0.58) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL27081892 | 0.78 | LTA4H (0.59) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL12130332 | 0.78 | LTA4H (0.52) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL30063063 | 0.78 | LTA4H (0.56) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL12130328 | 0.78 | LTA4H (0.52) | LTA4HKDM4EPSMB1PSMB5PSMB2 | |
| SCHEMBL545206 | 0.78 | LTA4H (0.56) | LTA4HKDM4EPSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231798-B1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8653087-B2 | Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | LTA4H 1947/4885KDM4E 2715/4885PSMB1 2031/4885 |
| US-20120094975-A1 | PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS | CCNT1, CCNA1, CCND1 | LTA4H 1519/4885KDM4E 1224/4885PSMB1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.